Retrospective analysis of hospital-acquired linezolid-nonsusceptible enterococci infection in Chongqing, China, 2011-2014

American Journal of Infection Control

Volumn 43, Issue 12, 2015, Pages e101-e106

  Jia, Xiaojiong ^a   Ma, Weijia ^a   Xu, Xiuyu ^a   Yang, Shuangshuang ^a   Zhang, Liping ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Enterococci; Epidemiology; Infections; Linezolid nonsusceptible

Indexed keywords

CEPHALOSPORIN DERIVATIVE; LINEZOLID; ANTIINFECTIVE AGENT;

AGED; ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; ENTEROCOCCAL INFECTION; FEMALE; GALLBLADDER DISEASE; HOSPITAL BASED CASE CONTROL STUDY; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; INFECTION; INFECTION RISK; LINEZOLID NONSUSCEPTIBLE ENTEROCOCCAL INFECTION; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; POLYMICROBIAL INFECTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; TEACHING HOSPITAL; ADULT; ANTIBIOTIC RESISTANCE; CASE CONTROL STUDY; CHINA; CROSS INFECTION; DRUG EFFECTS; ENTEROCOCCUS; GRAM-POSITIVE BACTERIAL INFECTIONS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; RISK FACTOR;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CHINA; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HOSPITALS, TEACHING; HUMANS; LINEZOLID; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84940062097     PISSN: 01966553     EISSN: 15273296     Source Type: Journal    
DOI: 10.1016/j.ajic.2015.07.027     Document Type: Article

References (25)

1. K.J. Shaw, and M.R. Barbachyn The oxazolidinones: past, present, and future Ann N Y Acad Sci 1241 2011 48 70
2. K.S. Long, and B. Vester Resistance to linezolid caused by modifications at its binding site on the ribosome Antimicrobial Agents Chemother 56 2012 603 612
3. R.E. Mendes, P.A. Hogan, J.M. Streit, R.N. Jones, and R.K. Flamm Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program: report of linezolid activity over 9 years (2004-12) J Antimicrob Chemother 69 2014 1582 1588
4. R.E. Mendes, R.K. Flamm, P.A. Hogan, J.E. Ross, and R.N. Jones Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States Antimicrobial Agents Chemother 58 2014 1243 1247
5. J.C. McGregor, D.M. Hartung, G.P. Allen, R.A. Taplitz, R. Traver, T. Tong, and et al. Risk factors associated with linezolid-nonsusceptible enterococcal infections Am J Infect Control 40 2012 886 887
6. E.M. Santayana, S.A. Grim, W.M. Janda, J.E. Layden, T.A. Lee, and N.M. Clark Risk factors and outcomes associated with vancomycin-resistant Enterococcus infections with reduced susceptibilities to linezolid Diagn Microbiol Infect Dis 74 2012 39 42
7. M.P. Pai, K.A. Rodvold, P.C. Schreckenberger, R.D. Gonzales, J.M. Petrolatti, and J.P. Quinn Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium Clin Infect Dis 35 2002 1269 1272
8. K. Hayakawa, D. Marchaim, J.M. Pogue, K. Ho, S. Parveen, P. Nanjireddy, and et al. Predictors and outcomes of linezolid-resistant vancomycin-resistant Enterococcus: a case-case-control study Am J Infect Control 40 2012 261 263
9. J.M. Pogue, D.L. Paterson, A.W. Pasculle, and B.A. Potoski Determination of risk factors associated with isolation of linezolid-resistant strains of vancomycin-resistant Enterococcus Infect Control Hosp Epidemiol 28 2007 1382 1388
10. K.S. Kaye, A.D. Harris, M. Samore, and Y. Carmeli The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance Infect Control Hosp Epidemiol 26 2005 346 351
11. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard, 10th ed. CLSI document M07-A10. Wayne [PA]: CLSI, 2014.
12. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 23th informational supplement. CLSI document M100-S20. Wayne [PA]: CLSI, 2014.
13. J.S. Garner, W.R. Jarvis, T.G. Emori, T.C. Horan, and J.M. Hughes CDC definitions for nosocomial infections, 1988 Am J Infect Control 16 1988 128 140
14. S. Katz, A.B. Ford, R.W. Moskowitz, B.A. Jackson, and M.W. Jaffe Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function JAMA 185 1963 914 919
15. T.P. Lodise, P.S. McKinnon, V.H. Tam, and M.J. Rybak Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center Clin Infect Dis 34 2002 922 929
16. A.B. Onderdonk, J.G. Bartlett, T. Louie, N. Sullivan-Seigler, and S.L. Gorbach Microbial synergy in experimental intra-abdominal abscess Infect Immun 13 1976 22 26
17. A. Korgaonkar, U. Trivedi, K.P. Rumbaugh, and M. Whiteley Community surveillance enhances Pseudomonas aeruginosa virulence during polymicrobial infection Proc Natl Acad Sci U S A 110 2013 1059 1064
18. J.L. Murray, J.L. Connell, A. Stacy, K.H. Turner, and M. Whiteley Mechanisms of synergy in polymicrobial infections J Microbiol 52 2014 188 199
19. J.W. Leung, Y.L. Liu, T. Desta, E. Libby, J.F. Inciardi, and K. Lam Is there a synergistic effect between mixed bacterial infection in biofilm formation on biliary stents? Gastrointest Endosc 48 1988 250 257
20. A.G. Speer, P.B. Cotton, J. Rode, A.M. Seddon, C.R. Neal, J. Holton, and et al. Biliary stent blockage with bacterial biofilm Ann Intern Med 108 1988 546 553
21. J.W. Leung, T.K. Ling, R.C. Chan, S.W. Cheung, C.W. Lai, J.J. Sung, and et al. Antibiotics, biliary sepsis and bile duct stones Gastrointest Endosc 40 1994 716 721
22. R. Pallares, M. Pujol, C. Peña, J. Ariza, R. Martin, and F. Gudiol Cephalosporins as risk factor for nosocomial Enterococcus faecalis bacteremia. A matched case-control study Arch Intern Med 153 1993 1581 1586
23. C.J. Donskey The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens Clin Infect Dis 39 2004 219 226
24. N.I. Agudelo Higuita, and M.M. Huycke Enterococcal disease, epidemiology, and implications for treatment M.S. Gilmore, D.B. Clewell, Y. Ike, N. Shankar, Enterococci: from commensals to leading causes of drug resistant infection 2014 Massachusetts Eye and Ear Infirmary Boston [MA] 45 70
25. M.E. Falagas, and K.Z. Vardakas Benefit-risk assessment of linezolid for serious gram-positive bacterial infections Drug Saf 31 2008 753 768